Wegovy and Zepbound are both once-weekly GLP-1 injections approved for weight loss, but they work through different mechanisms and produce different average results. Zepbound (tirzepatide) targets two hormone receptors and outperformed Wegovy (semaglutide) in the first major head-to-head trial, while Wegovy carries a longer cardiovascular track record. The good news for patients: both are available as compounded versions through 503A-regulated pharmacies, which makes either option far more accessible.
A Tale of Two GLP-1s
If you have spent any time researching weight loss medications, you have seen these two names at the top of almost every list. Wegovy launched in 2021 and quickly became the most-prescribed branded GLP-1 for weight management. Zepbound arrived in late 2023 and immediately drew attention because clinical trials showed it produced roughly 50% more average weight loss than semaglutide.
But clinical averages do not tell the full story. Your personal response, medical history, side effect profile, and access to medication all factor into which option makes more sense for you. This article breaks down the science without oversimplifying it, so you can walk into a medical evaluation knowing exactly what to ask.
What Is Wegovy?
Wegovy is the brand name for semaglutide at the 2.4 mg weekly dose, manufactured by Novo Nordisk. The FDA approved it in June 2021 for chronic weight management in adults with obesity (BMI of 30 or above) or overweight (BMI of 27 or above) with at least one weight-related condition such as high blood pressure or type 2 diabetes.
Semaglutide is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone your gut naturally releases after eating, signaling your brain that you are full, slowing the rate at which your stomach empties, and reducing overall appetite. The result is a sustained reduction in caloric intake without the sensation of white-knuckling through hunger.
In the STEP 1 pivotal trial, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% on placebo. Wegovy also received an additional FDA indication in 2024 for reducing the risk of major cardiovascular events in adults with established heart disease and obesity or overweight.
What Is Zepbound?
Zepbound is the brand name for tirzepatide at doses used for weight loss, manufactured by Eli Lilly. The FDA approved it for chronic weight management in November 2023. You may also know tirzepatide as Mounjaro, which is the same active ingredient approved for type 2 diabetes.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. In addition to activating GLP-1 receptors, it also activates glucose-dependent insulinotropic polypeptide (GIP) receptors. That second mechanism gives it an additional lever for appetite regulation and energy metabolism.
A simple way to frame it: Wegovy turns one appetite dial down. Zepbound turns two. In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 20.9% of body weight at 72 weeks versus 3.1% on placebo. And in the first head-to-head randomized trial comparing the two drugs directly (NEJM, 2025), tirzepatide produced greater weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%.
Wegovy vs Zepbound: Side-by-Side Comparison
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Dosing schedule | Once weekly injection (0.25 mg up to 2.4 mg) | Once weekly injection (2.5 mg up to 15 mg) |
| Average weight loss (pivotal trials) | ~14.9% at 68 weeks (STEP 1) | ~20.9% at 72 weeks (SURMOUNT-1) |
| Head-to-head result (NEJM 2025) | -13.7% at 72 weeks | -20.2% at 72 weeks |
| FDA approval for weight loss | June 2021 | November 2023 |
| Additional FDA indications | Cardiovascular risk reduction | Moderate-to-severe obstructive sleep apnea |
| Brand list price (approximate) | Over $1,300/month | Over $1,000/month |
| Compounded alternative | Compounded semaglutide (503A pharmacy) | Compounded tirzepatide (503A pharmacy) |
| Compounded option at Telezen | Yes | Yes |
Brand pricing above reflects typical list price without insurance. Telezen MD works with 503A-regulated compounding pharmacies, which can significantly reduce the financial investment for eligible patients.
Weight Loss Results: Reading the Data Accurately
Clinical percentages can feel abstract. Here is a grounded way to think about them. If a person starts at 220 pounds, 14.9% weight loss equals about 33 pounds. At 20.2%, that same starting weight translates to roughly 44 pounds.
The first randomized head-to-head trial, published in the New England Journal of Medicine in 2025, confirmed what earlier separate trials suggested: tirzepatide produces greater average weight loss. Participants on tirzepatide also reduced waist circumference more (-18.4 cm versus -13.0 cm). Close to 32% of the tirzepatide group lost at least a quarter of their body weight, compared to 16% of the semaglutide group.
Two critical caveats apply. First, “average” is not the same as “yours.” Individual response to both medications varies considerably. Some patients do exceptionally well on semaglutide; others plateau faster on tirzepatide and need a dosing adjustment. Second, weight loss alone is not the only goal. Cardiovascular risk reduction, sleep apnea improvement, blood sugar management, and overall quality of life all factor into which medication a provider might recommend.
How the Two Mechanisms Affect You Differently
Both medications slow gastric emptying, reduce appetite, and improve insulin sensitivity. The GLP-1 pathway handles appetite signaling in the brain and slows the speed at which food leaves your stomach, which keeps you feeling full longer.
The additional GIP mechanism in tirzepatide appears to enhance fat metabolism and may improve how fat cells respond to insulin. Researchers believe this complementary action is what drives the additional weight loss seen in tirzepatide trials.
Practically, this means some patients who experience a plateau on semaglutide may find tirzepatide more effective at higher doses. Conversely, some patients tolerate semaglutide better because the single-receptor approach produces a gentler side effect profile at equivalent weight loss outcomes.
Side Effects: What Both Share and Where They Differ
The side effect profiles for Wegovy and Zepbound overlap significantly. Both commonly cause gastrointestinal symptoms, particularly during the dose escalation phase: nausea, diarrhea, constipation, and vomiting. Both carry a boxed warning about thyroid C-cell tumors observed in rodent studies and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Both also delay gastric emptying, which is relevant for surgical anesthesia and for anyone taking oral medications whose absorption depends on stomach timing. Both warn about pancreatitis and gallbladder disease as less common but serious risks.
One notable difference: tirzepatide’s label specifically warns about oral contraceptive absorption because of delayed gastric emptying, recommending a barrier method for at least four weeks after starting or increasing the dose. If you use oral birth control, that is an important conversation to have with your provider.
Wegovy now also comes in an oral daily pill form. It requires an empty stomach and a 30-minute waiting period before eating or drinking. The injection format remains the standard for both medications.
Brand Cost and the Case for Compounded GLP-1s
Brand-name GLP-1 medications represent a significant ongoing investment. Wegovy typically lists above $1,300 per month, and Zepbound runs above $1,000 per month, with costs varying by pharmacy and insurance coverage. Even patients with insurance often face high out-of-pocket amounts, prior authorization hurdles, or coverage that changes from year to year.
This is where compounded GLP-1s change the conversation. 503A-regulated compounding pharmacies can prepare semaglutide (the Wegovy equivalent) and tirzepatide (the Zepbound equivalent) as prescribed by a licensed provider at a considerably lower investment point. These are not research-grade peptides from unregulated sources. 503A pharmacies operate under FDA oversight and prepare medications to a specific patient prescription.
Telezen MD prescribes compounded semaglutide and compounded tirzepatide through 503A FDA-regulated pharmacies. The medication ships directly to your door. You do not have to call pharmacies, chase insurance approvals, or manage prior authorizations. For many patients, this access model makes a medically supervised GLP-1 program realistic for the first time.
You can explore both options at Telezen: compounded semaglutide and compounded tirzepatide. If you want to compare the full GLP-1 offering, visit telezenmd.com/glp-1-weight-loss-treatment-online.
Why the Prescription Is Just the Beginning
Getting access to medication is one challenge. Using it effectively is another. GLP-1 medications work best when paired with behavioral and nutritional strategies that help you build habits that last beyond the medication itself.
Telezen MD was built with that gap in mind. Every patient gets access to two programs that most GLP-1 providers do not offer at all.
The GLP-1 Nutrition Protocol
The GLP-1 Nutrition Protocolâ„¢ is a free, purpose-built nutrition program included with every Telezen membership. It covers seven modules and 26 lessons designed specifically for patients on GLP-1 therapy, addressing the unique nutritional challenges that come with appetite suppression: getting enough protein, maintaining muscle, managing nausea around meals, and structuring eating patterns that sustain weight loss without nutrient deficiency.
Lose It for Life
Lose It for Lifeâ„¢ is a behavioral program created by Lina Viner using The Rewire Methodâ„¢. Ten modules work through the psychological and emotional patterns around food, appetite, and identity that GLP-1 medications address physiologically but not behaviorally. It is free for all Telezen patients and built to support long-term results rather than short-term scale wins.
“Medical science takes the weight off. Mind science keeps it off.”
Concierge Support
Telezen patients have access to a real person via call or text at any time. Questions about dosing, side effects, next steps, or anything else about your treatment get answered by someone who knows your case, not a chatbot or a generic FAQ page.
How to Get Started
The Telezen patient process is straightforward and fully online:
- Complete a digital intake form that includes your medical history and current health information.
- Choose a treatment plan within the intake form.
- Submit your intake.
- The Telezen medical team reviews your intake within 24 hours and issues a prescription if appropriate.
- Your medication ships directly to your door from a 503A-regulated compounding pharmacy.
There are no in-office visits required and no waiting room delays. The entire process is designed to remove the friction that keeps people from getting medically appropriate care.
Frequently Asked Questions
Is Zepbound better than Wegovy for weight loss?
In the first head-to-head randomized trial (NEJM 2025), tirzepatide produced greater average weight loss than semaglutide at 72 weeks: -20.2% versus -13.7%. Tirzepatide targets two hormone receptors (GIP and GLP-1) versus one (GLP-1 only), which appears to drive greater average results. That said, individual response varies, and “better on average” does not always mean “better for you.” A licensed provider can help determine which is the right fit based on your health history.
Can I get Wegovy or Zepbound without insurance?
Yes. Telezen MD prescribes compounded semaglutide (equivalent to Wegovy) and compounded tirzepatide (equivalent to Zepbound) through 503A FDA-regulated pharmacies. Compounded versions are significantly more accessible from a cost standpoint than brand-name options. You do not need insurance to use Telezen. Brand-name Wegovy and Zepbound require a prescription from a licensed provider regardless of coverage.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide, but they are approved for different purposes and at different doses. Ozempic is approved for type 2 diabetes management and comes in doses up to 2 mg weekly. Wegovy is approved specifically for weight management at the 2.4 mg weekly dose. The mechanism is the same; the indication and dose differ.
What is the difference between Zepbound and Mounjaro?
Same situation as Wegovy and Ozempic. Both contain tirzepatide. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The active ingredient, dosing range, and mechanism are identical.
Are compounded GLP-1s safe?
Compounded medications prepared by 503A-regulated pharmacies are subject to FDA oversight and are prepared to a specific patient prescription by a licensed provider. They are not the same as unregulated “research-grade” peptides sold online without a prescription. Telezen MD only uses 503A-regulated compounding pharmacies. Compounded medications are not FDA-approved products in the same way that brand-name Wegovy and Zepbound are, meaning the FDA has not independently reviewed them for safety and efficacy. Always work with a licensed medical provider rather than sourcing GLP-1 medications independently.
How long does it take to see results on Wegovy or Zepbound?
Most patients notice reduced appetite within the first few weeks, but significant scale changes typically appear after 8 to 12 weeks as the dose escalates. Clinical trials measured outcomes at 68 to 72 weeks, which reflects the longer arc of how these medications work. Consistency, nutrition support, and behavioral strategies all influence how quickly and sustainably results build.
The Bottom Line
Wegovy and Zepbound are both clinically validated weekly GLP-1 injections that produce meaningful weight loss when combined with lifestyle changes. Zepbound’s dual mechanism gives it an edge in average weight loss outcomes. Wegovy has a longer cardiovascular safety track record. Neither is definitively superior for every patient.
What matters most is getting started with the right medical support. At Telezen MD, patients get access to both compounded semaglutide and compounded tirzepatide through 503A pharmacies, the GLP-1 Nutrition Protocolâ„¢, Lose It for Lifeâ„¢ by Lina Viner, and concierge support throughout the process. The medical team reviews every intake within 24 hours.
Visit telezenmd.com/glp-1-weight-loss-treatment-online to learn more or begin your intake today.
Sources
- Jastreboff AM, et al. “Tirzepatide vs. Semaglutide for Obesity.” New England Journal of Medicine. 2025. nejm.org
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022 (SURMOUNT-1). nejm.org
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021 (STEP 1). nejm.org
- Gokhale P, et al. “Comparative Effectiveness of GLP-1 Receptor Agonists for Weight Loss: A Meta-Analysis.” Obesity. 2026. onlinelibrary.wiley.com
- FDA. Wegovy (semaglutide) Prescribing Information. fda.gov
- FDA. Zepbound (tirzepatide) Prescribing Information. fda.gov
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. GLP-1 medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
